Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | CA12 | O43570 | 4/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20991378 | 0.92 | TSHR (0.54) | TSHRCA12CA14CA7CA9 | |
| SCHEMBL18724781 | 0.92 | TSHR (0.54) | TSHRCA12CA14CA7CA9 | |
| SCHEMBL3989212 | 0.89 | TSHR (0.57) | TSHRCA12CA14CA7CA9 | |
| Hydrochloric Acid SCHEMBL5595765 | 0.86 | TSHR (0.55) | TSHRCA12CA14CA7CA9 | |
| SCHEMBL15782723 | 0.86 | TSHR (0.46) | TSHRCA12CA14CA7CA9 | |
| SCHEMBL27444159 | 0.83 | LMNA (0.55) | TSHREPHX2LMNAALDH1A1 | |
| SCHEMBL10001841 | 0.83 | TSHR (0.38) | TSHRCA12CA14CA7CA9 | |
| SCHEMBL3695439 | 0.82 | EPHX2 (0.60) | TSHREPHX2LMNAALDH1A1 | |
| SCHEMBL27756883 | 0.82 | TSHR (0.52) | TSHRCA12CA14CA7CA9 | |
| SCHEMBL12176701 | 0.82 | CYP1A2 (0.52) | TSHRALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023056033-A1 | LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERING CIRCULAR POLYNUCLEOTIDES | ORNA THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| CN-106977584-B | Compound for targeted ubiquitination degradation of PLK1 and BRD4 proteins and application thereof | JILIN UNIVERSITY (CN) | 2019-12-06 | — | — | CN | disclosed |
| US-10421778-B2 | Isoform-selective lysine deacetylase inhibitors | WASHINGTON UNIVERSITY (US) | 2019-09-24 | — | — | US | disclosed |
| US-10246478-B2 | Polyene macrolide derivative | SHIONOGI & CO., LTD. (JP) | 2019-04-02 | — | — | US | disclosed |
| WO-2018081480-A1 | LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2018-05-03 | — | — | WO | disclosed |
| CN-106977584-A | Target compound and its application of ubiquitination degraded PLK1 and BRD4 albumen | 吉林大学 | 2017-07-25 | — | — | CN | disclosed |
| WO-2017117528-A1 | LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics, Inc. (CA) | 2017-07-06 | — | — | WO | disclosed |
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| WO-2017042828-A2 | PROCESS FOR THE PREPARATION OF SELEXIPAG AND INTERMEDIATES THEREOF | MEGAFINE PHARMA (P) LTD. (IN) | 2017-03-16 | — | — | WO | disclosed |
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | GILEAD SCIENCES, INC. | 2016-11-17 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-7250444-B2 | Pyrrole-based HMG-CoA reductase inhibitors | PFIZER INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250444-B2 | Pyrrole-based HMG-CoA reductase inhibitors | PFIZER INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-5618814-A | Trisubstituted pyrimido [5,4-d] pyrimidines for modulating multi-drug resistance and pharmaceutical compositions containing these compounds | DR. KARL THOMAE GMBH (DE) | 1997-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | TSHR 94/4885CA12 4580/4885CA14 4367/4885 |
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | ERG28, RPL23, RPL10 | TSHR 4491/4885CA12 3264/4885CA14 2571/4885 |
| US-10246478-B2 | Polyene macrolide derivative | ERG28, RPL23, RPL10 | TSHR 4491/4885CA12 3264/4885CA14 2571/4885 |
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | IDO1, IDO2, INMT | TSHR 1752/4885CA12 4625/4885CA14 4607/4885 |
| US-10421778-B2 | Isoform-selective lysine deacetylase inhibitors | DOT1L, KDM1A, HDAC1 | TSHR 4222/4885CA12 4729/4885CA14 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.